These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 26602217)
1. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. Sanyal AJ; Neuschwander-Tetri BA; Tonascia J Gastroenterology; 2016 Jan; 150(1):11-3. PubMed ID: 26602217 [No Abstract] [Full Text] [Related]
2. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. Byrne CD; Targher G Gastroenterology; 2016 Jan; 150(1):7-10. PubMed ID: 26602219 [No Abstract] [Full Text] [Related]
3. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. Sanyal AJ; Miller V Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092 [No Abstract] [Full Text] [Related]
4. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814 [TBL] [Abstract][Full Text] [Related]
5. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R; Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326 [TBL] [Abstract][Full Text] [Related]
6. Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus. Takemoto M; Yamaga M; Furuichi Y; Yokote K J Am Geriatr Soc; 2015 Jun; 63(6):1271-3. PubMed ID: 26096415 [No Abstract] [Full Text] [Related]
7. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Vos MB; Dimick-Santos L; Mehta R; Omokaro SO; Taminiau J; Schabel E; Kleiner DE; Szitanyi P; Socha P; Schwimmer JB; Noviello S; Silberg DG; Torstenson R; Miller V; Lavine JE; Gastroenterology; 2019 Dec; 157(6):1448-1456.e1. PubMed ID: 31520612 [No Abstract] [Full Text] [Related]
8. NONALCOHOLIC FATTY LIVER DISEASE AND ITS COMPLICATIONS--ASSESSING THE POPULATION AT RISK. A SMALL SERIES REPORT AND LITERATURE REVIEW. Livadariu R; Timofte D; Danilă R; Ionescu L; Diaconu C; Soroceanu P; Sângeap AM; Drug VL; Trifan A Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):346-52. PubMed ID: 26204635 [TBL] [Abstract][Full Text] [Related]
17. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. Georgoulis M; Fragopoulou E; Kontogianni MD; Margariti A; Boulamatsi O; Detopoulou P; Tiniakos D; Zafiropoulou R; Papatheodoridis G Nutr Res; 2015 Jan; 35(1):41-8. PubMed ID: 25530013 [TBL] [Abstract][Full Text] [Related]
18. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Amacher DE Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636 [TBL] [Abstract][Full Text] [Related]
19. A need for speed: Signals in drug development. Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053 [No Abstract] [Full Text] [Related]
20. In vivo (1)H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: an animal study at 9.4 T. Lee Y; Jee HJ; Noh H; Kang GH; Park J; Cho J; Cho JH; Ahn S; Lee C; Kim OH; Oh BC; Kim H Magn Reson Med; 2013 Sep; 70(3):620-9. PubMed ID: 23023916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]